docs/_posts/Ahmetemintek/2022-11-16-abbreviation_category_mapper_en.md
docs/_posts/Ahmetemintek/2022-11-18-kegg_disease_mapper_en.md
docs/_posts/Ahmetemintek/2022-11-21-kegg_drug_mapper_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_anatomy_general_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_anatomy_granular_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_biomarker_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_demographics_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_diagnosis_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_posology_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_response_to_treatment_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_test_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_therapy_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_tnm_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_unspecific_posology_en.md
docs/_posts/Cabir40/2022-11-22-ner_clinical_bert_ro.md
docs/_posts/Cabir40/2022-11-22-ner_deid_generic_bert_ro.md
docs/_posts/Cabir40/2022-11-22-ner_living_species_300_es.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_administration_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_administration_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_agreement_and_declaration_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_asset_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_consulting_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_contribution_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_control_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_credit_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_custodian_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_distribution_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_employment_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_equity_distribution_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_exchange_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_exclusive_license_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_executive_employment_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_general_distribution_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_guarantee_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_indemnification_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_intercreditor_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_investment_subadvisory_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_joint_filing_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_joint_filing_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_lease_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_letter_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_letter_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_limited_partnership_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_loan_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_note_purchase_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_operating_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_rights_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_separation_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_settlement_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_trust_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_voting_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_loan_and_security_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_management_contract_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_master_lease_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_master_repurchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_note_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_operating_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_participation_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_pledge_and_security_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_rights_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_securities_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_security_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_separation_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_service_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_settlement_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_share_exchange_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_stock_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_stockholder_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_sublease_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_subscription_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_terms_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_transition_services_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_trust_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_voting_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-30-legner_ronec_ro.md
docs/_posts/bunyamin-polat/2022-12-01-finclf_sec_filings_en.md
docs/_posts/dcecchini/2022-11-30-finner_earning_calls_generic_sm_en.md
docs/_posts/dcecchini/2022-11-30-finner_earning_calls_specific_sm_en.md
docs/_posts/dcecchini/2022-11-30-finner_financial_xlarge_en.md
docs/_posts/gadde5300/2022-11-15-longformer_legal_embeddings_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d100_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d100_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d300_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d300_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d50_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d50_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d100_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d100_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d300_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d300_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d50_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d50_uncased_es.md
docs/_posts/gadde5300/2022-11-25-legclf_additional_covenants_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_bulletin_boards_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_conversion_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_delays_or_omissions_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_escrow_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_exclusive_remedy_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_expenses_indemnity_damage_waiver_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_expiration_date_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_formation_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_hazardous_materials_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_indemnification_and_insurance_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_leave_of_absence_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_limitation_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_non_contravention_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_ofac_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_opinions_of_counsel_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_other_definitions_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_paid_holidays_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_prepayment_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_register_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_risk_of_loss_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_subcontracting_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_third_party_rights_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_vacancies_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_w_i_t_n_e_s_s_e_t_h_clause_en.md
docs/_posts/gadde5300/2022-11-26-longformer_legal_base_8192_es.md
docs/_posts/gadde5300/2022-11-30-finner_german_financial_entities_de.md
docs/_posts/josejuanmartinez/2022-10-20-legal_longformer_base_en.md
docs/_posts/josejuanmartinez/2022-11-16-legclf_termination_md_en.md
docs/_posts/josejuanmartinez/2022-11-16-legclf_whereas_md_en.md
docs/_posts/josejuanmartinez/2022-11-17-legclf_cuad_signers_clause_en.md
docs/_posts/josejuanmartinez/2022-11-17-legclf_introduction_clause_en.md
docs/_posts/josejuanmartinez/2022-11-21-legclf_dates_sm_en.md
docs/_posts/josejuanmartinez/2022-11-21-legner_dates_sm_en.md
docs/_posts/josejuanmartinez/2022-11-23-finsum_news_headers_md_en.md
docs/_posts/josejuanmartinez/2022-11-23-finsum_news_xs_en.md
docs/_posts/josejuanmartinez/2022-11-24-finclf_earning_broker_10k_en.md
docs/_posts/josejuanmartinez/2022-11-24-finsum_news_headers_lg_en.md
docs/_posts/josejuanmartinez/2022-11-24-finsum_news_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_cuad_whereas_clause_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_employee_benefit_plans_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_grievance_procedure_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_indemnification_and_contribution_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_indemnification_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_introduction_clause_cuad_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_method_of_payment_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_power_of_attorney_md_en.md
docs/_posts/josejuanmartinez/2022-11-28-finre_earning_calls_sm_en.md
docs/_posts/josejuanmartinez/2022-11-28-legclf_cuad_confidentiality_clause_en.md
docs/_posts/josejuanmartinez/2022-11-28-legclf_cuad_obligations_clause_en.md
docs/_posts/josejuanmartinez/2022-11-30-legclf_cuad_force_majeure_clause_en.md
docs/_posts/josejuanmartinez/2022-11-30-legner_force_majeure_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_contract_doc_parties_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_grants_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_indemnifications_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_termination_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_warranty_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_whereas_md_en.md
docs/_posts/josejuanmartinez/2022-12-02-finner_10q_xlbr_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_diagnosis_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_general_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_therapy_pipeline_en.md
docs/_posts/maziyarpanahi/2022-11-28-t5_grammar_error_corrector_en.md
docs/_posts/Ahmetemintek/2022-11-16-abbreviation_category_mapper_en.md
docs/_posts/Ahmetemintek/2022-11-18-kegg_disease_mapper_en.md
docs/_posts/Ahmetemintek/2022-11-21-kegg_drug_mapper_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_anatomy_general_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_anatomy_granular_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_biomarker_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_demographics_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_diagnosis_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_posology_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_response_to_treatment_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_test_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_therapy_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_tnm_en.md
docs/_posts/Ahmetemintek/2022-11-24-ner_oncology_unspecific_posology_en.md
docs/_posts/Cabir40/2022-11-22-ner_clinical_bert_ro.md
docs/_posts/Cabir40/2022-11-22-ner_deid_generic_bert_ro.md
docs/_posts/Cabir40/2022-11-22-ner_living_species_300_es.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_administration_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_administration_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_agreement_and_declaration_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_asset_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_consulting_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_contribution_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_control_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_credit_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_custodian_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_distribution_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_employment_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_equity_distribution_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_exchange_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_exclusive_license_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_executive_employment_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_general_distribution_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_guarantee_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_indemnification_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_intercreditor_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_investment_subadvisory_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_joint_filing_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_joint_filing_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_lease_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_letter_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_letter_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_limited_partnership_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_loan_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_note_purchase_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_operating_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_rights_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_separation_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_settlement_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_trust_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-24-legclf_voting_agreement_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_loan_and_security_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_management_contract_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_master_lease_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_master_repurchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_note_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_operating_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_participation_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_pledge_and_security_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_rights_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_securities_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_security_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_separation_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_service_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_settlement_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_share_exchange_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_stock_purchase_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_stockholder_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_sublease_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_subscription_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_terms_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_transition_services_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_trust_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-25-legclf_voting_agreement_bert_en.md
docs/_posts/bunyamin-polat/2022-11-30-legner_ronec_ro.md
docs/_posts/bunyamin-polat/2022-12-01-finclf_sec_filings_en.md
docs/_posts/dcecchini/2022-11-30-finner_earning_calls_generic_sm_en.md
docs/_posts/dcecchini/2022-11-30-finner_earning_calls_specific_sm_en.md
docs/_posts/dcecchini/2022-11-30-finner_financial_xlarge_en.md
docs/_posts/gadde5300/2022-11-15-longformer_legal_embeddings_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d100_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d100_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d300_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d300_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d50_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_cbow_legal_d50_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d100_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d100_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d300_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d300_uncased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d50_cased_es.md
docs/_posts/gadde5300/2022-11-15-word2vec_skipgram_legal_d50_uncased_es.md
docs/_posts/gadde5300/2022-11-25-legclf_additional_covenants_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_bulletin_boards_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_conversion_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_delays_or_omissions_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_escrow_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_exclusive_remedy_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_expenses_indemnity_damage_waiver_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_expiration_date_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_formation_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_hazardous_materials_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_indemnification_and_insurance_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_leave_of_absence_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_limitation_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_non_contravention_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_ofac_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_opinions_of_counsel_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_other_definitions_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_paid_holidays_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_prepayment_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_register_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_risk_of_loss_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_subcontracting_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_third_party_rights_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_vacancies_clause_en.md
docs/_posts/gadde5300/2022-11-25-legclf_w_i_t_n_e_s_s_e_t_h_clause_en.md
docs/_posts/gadde5300/2022-11-26-longformer_legal_base_8192_es.md
docs/_posts/gadde5300/2022-11-30-finner_german_financial_entities_de.md
docs/_posts/josejuanmartinez/2022-10-20-legal_longformer_base_en.md
docs/_posts/josejuanmartinez/2022-11-16-legclf_termination_md_en.md
docs/_posts/josejuanmartinez/2022-11-16-legclf_whereas_md_en.md
docs/_posts/josejuanmartinez/2022-11-17-legclf_cuad_signers_clause_en.md
docs/_posts/josejuanmartinez/2022-11-17-legclf_introduction_clause_en.md
docs/_posts/josejuanmartinez/2022-11-21-legclf_dates_sm_en.md
docs/_posts/josejuanmartinez/2022-11-21-legner_dates_sm_en.md
docs/_posts/josejuanmartinez/2022-11-23-finsum_news_headers_md_en.md
docs/_posts/josejuanmartinez/2022-11-23-finsum_news_xs_en.md
docs/_posts/josejuanmartinez/2022-11-24-finclf_earning_broker_10k_en.md
docs/_posts/josejuanmartinez/2022-11-24-finsum_news_headers_lg_en.md
docs/_posts/josejuanmartinez/2022-11-24-finsum_news_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_cuad_whereas_clause_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_employee_benefit_plans_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_grievance_procedure_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_indemnification_and_contribution_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_indemnification_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_introduction_clause_cuad_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_method_of_payment_md_en.md
docs/_posts/josejuanmartinez/2022-11-25-legclf_power_of_attorney_md_en.md
docs/_posts/josejuanmartinez/2022-11-28-finre_earning_calls_sm_en.md
docs/_posts/josejuanmartinez/2022-11-28-legclf_cuad_confidentiality_clause_en.md
docs/_posts/josejuanmartinez/2022-11-28-legclf_cuad_obligations_clause_en.md
docs/_posts/josejuanmartinez/2022-11-30-legclf_cuad_force_majeure_clause_en.md
docs/_posts/josejuanmartinez/2022-11-30-legner_force_majeure_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_contract_doc_parties_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_grants_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_indemnifications_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_termination_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_warranty_md_en.md
docs/_posts/josejuanmartinez/2022-12-01-legner_whereas_md_en.md
docs/_posts/josejuanmartinez/2022-12-02-finner_10q_xlbr_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_diagnosis_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_general_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_therapy_pipeline_en.md
docs/_posts/maziyarpanahi/2022-11-28-t5_grammar_error_corrector_en.md
